O
Oscar Arrieta
Researcher at National Autonomous University of Mexico
Publications - 407
Citations - 18104
Oscar Arrieta is an academic researcher from National Autonomous University of Mexico. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 42, co-authored 329 publications receiving 14124 citations. Previous affiliations of Oscar Arrieta include Fox Chase Cancer Center & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
Hossein Borghaei,Luis Paz-Ares,Leora Horn,D. R. Spigel,M. Steins,Neal Ready,L.Q. Chow,Everett E. Vokes,Enriqueta Felip,Esther Holgado,F. Barlesi,M. Kohlhufl,Oscar Arrieta,Marco Angelo Burgio,J. Fayette,H. Lena,Elena Poddubskaya,David E. Gerber,Scott N. Gettinger,Charles M. Rudin,Naiyer A. Rizvi,L. Crina,G. R. Blumenschein,Scott J. Antonia,C. Dorange,C. T. Harbison,F. Graf Finckenstein,Julie R. Brahmer +27 more
TL;DR: Nivolumab was associated with even greater efficacy than docetaxel across all end points in subgroups defined according to prespecified levels of tumor-membrane expression (≥1, ≥5%, and ≥10%) of the PD-1 ligand.
Journal ArticleDOI
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Edward B. Garon,Tudor Ciuleanu,Oscar Arrieta,Kumar Prabhash,Konstantinos N. Syrigos,Tuncay Göksel,Keunchil Park,Vera Gorbunova,Ruben Dario Kowalyszyn,Joanna Pikiel,Grzegorz Czyzewicz,Sergey Orlov,Conrad R. Lewanski,Michael Thomas,Paolo Bidoli,Shaker R. Dakhil,Steven J.M. Gans,Joo Hang Kim,Alexandru Grigorescu,Nina Karaseva,Martin Reck,Federico Cappuzzo,Ekaterine Alexandris,Andreas Sashegyi,Sergey Yurasov,Maurice Pérol +25 more
TL;DR: Ramucirumab plus docetaxel improves survival as second-line treatment of patients with stage IV NSCLC after platinum-based therapy and is registered with ClinicalTrials.gov.
Journal ArticleDOI
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).
Leora Horn,David R. Spigel,Everett E. Vokes,Esther Holgado,Neal Ready,Martin Steins,Elena Poddubskaya,Hossein Borghaei,Enriqueta Felip,Luis Paz-Ares,Adam Pluzanski,Karen L. Reckamp,Marco Angelo Burgio,Martin Kohlhaeufl,David M. Waterhouse,Fabrice Barlesi,Scott J. Antonia,Oscar Arrieta,Jérôme Fayette,Lucio Crinò,Naiyer A. Rizvi,Martin Reck,Matthew D. Hellmann,William J. Geese,Ang Li,Anne Blackwood-Chirchir,Diane Healey,Julie R. Brahmer,Wilfried Eberhardt +28 more
TL;DR: Nivolumab provides long-term clinical benefit and a favorable tolerability profile compared with docetaxel in previously treated patients with advanced NSCLC and is reported on in a pooled analysis of the two studies.
Journal ArticleDOI
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases
Everett E. Vokes,Neal Ready,Enriqueta Felip,Leora Horn,Marco Angelo Burgio,S.J. Antonia,O. Aren Frontera,Scott N. Gettinger,Esther Holgado,David R. Spigel,David M. Waterhouse,Manuel Domine,Marina Chiara Garassino,Laura Q.M. Chow,George R. Blumenschein,Fabrice Barlesi,Bruno Coudert,Justin F. Gainor,Oscar Arrieta,Julie R. Brahmer,Charles Butts,Martin Steins,William J. Geese,Ang Li,Diane Healey,L. Crinò +25 more
TL;DR: In this article, the anti-programmed death-1 antibody nivolumab versus docetaxel was compared in patients with previously treated advanced squamous (CheckMate 017) and nonsquamous NSCLC.
Journal ArticleDOI
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
Hossein Borghaei,Scott N. Gettinger,Everett E. Vokes,Laura Q.M. Chow,Marco Angelo Burgio,Javier de Castro Carpeño,Adam Pluzanski,Oscar Arrieta,Osvaldo Arén Frontera,Rita Chiari,Charles Butts,Joanna Wojcik-Tomaszewska,Bruno Coudert,Marina Chiara Garassino,Neal Ready,Enriqueta Felip,Miriam Alonso Garcia,David M. Waterhouse,Manuel Domine,Fabrice Barlesi,Scott J. Antonia,Markus Wohlleber,David E. Gerber,Grzegorz Czyzewicz,David R. Spigel,Lucio Crinò,Wilfried Enst Erich Eberhardt,Ang Li,S. Marimuthu,Julie R. Brahmer +29 more
TL;DR: In two phase III trials (CheckMate 017 and CheckMate 057), nivolumab showed an improvement in o... as mentioned in this paper, and showed an improved lung cancer survival.